Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials.

Literature DB >> 29607123

Anti-angiogenic therapy in nonsquamous non-small cell lung cancer (NSCLC) with tyrosine kinase inhibition (TKI) that targets the VEGF receptor (VEGFR): perspective on phase III clinical trials.

Sha'Shonda L Revels¹, Jay M Lee¹.

Abstract

Entities: Disease Gene

Year: 2018 PMID： 29607123 PMCID： PMC5864582 DOI： 10.21037/jtd.2018.01.105

Source DB: PubMed Journal: J Thorac Dis ISSN： 2072-1439 Impact factor: 2.895

× No keyword cloud information.

13 in total

1. Understanding and targeting resistance to anti-angiogenic therapies.

Authors: Jeffrey M Clarke; Herbert I Hurwitz
Journal: J Gastrointest Oncol Date: 2013-09

2. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates.

Authors: Sonja Loges; Thomas Schmidt; Peter Carmeliet
Journal: Genes Cancer Date: 2010-01

3. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis.

Authors: K Kubota; Y Ichinose; G Scagliotti; D Spigel; J H Kim; T Shinkai; K Takeda; S-W Kim; T-C Hsia; R K Li; B J Tiangco; S Yau; W-T Lim; B Yao; Y-J Hei; K Park
Journal: Ann Oncol Date: 2014-01-13 Impact factor: 32.976

4. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

Authors: Anthony Polverino; Angela Coxon; Charlie Starnes; Zobedia Diaz; Thomas DeMelfi; Ling Wang; James Bready; Juan Estrada; Russell Cattley; Stephen Kaufman; Danlin Chen; Yongmei Gan; Gondi Kumar; James Meyer; Sesha Neervannan; Gonzalo Alva; Jane Talvenheimo; Silvia Montestruque; Andrew Tasker; Vinod Patel; Robert Radinsky; Richard Kendall
Journal: Cancer Res Date: 2006-09-01 Impact factor: 12.701

5. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer.

Authors: G R Blumenschein; F Kabbinavar; H Menon; T S K Mok; J Stephenson; J T Beck; K Lakshmaiah; K Reckamp; Y-J Hei; K Kracht; Y-N Sun; R Sikorski; L Schwartzberg
Journal: Ann Oncol Date: 2011-02-14 Impact factor: 32.976

6. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

Authors: Giorgio V Scagliotti; Ihor Vynnychenko; Keunchil Park; Yukito Ichinose; Kaoru Kubota; Fiona Blackhall; Robert Pirker; Rinat Galiulin; Tudor-Eliade Ciuleanu; Oleksandr Sydorenko; Mircea Dediu; Zsolt Papai-Szekely; Natividad Martinez Banaclocha; Sheryl McCoy; Bin Yao; Yong-Jiang Hei; Francesco Galimi; David R Spigel
Journal: J Clin Oncol Date: 2012-07-02 Impact factor: 44.544

Review 7. Epidemiology of lung cancer.

Authors: Carole A Ridge; Aoife M McErlean; Michelle S Ginsberg
Journal: Semin Intervent Radiol Date: 2013-06 Impact factor: 1.513

8. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors: Kaoru Kubota; Hiroshige Yoshioka; Fumihiro Oshita; Toyoaki Hida; Kiyotaka Yoh; Hidetoshi Hayashi; Terufumi Kato; Hiroyasu Kaneda; Kazuhiko Yamada; Hiroshi Tanaka; Yukito Ichinose; Keunchil Park; Eun Kyung Cho; Kyung-Hee Lee; Chih-Bin Lin; James Chih-Hsin Yang; Kaori Hara; Takayuki Asato; Kazuhiko Nakagawa
Journal: J Clin Oncol Date: 2017-09-13 Impact factor: 44.544

9. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Authors: Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold
Journal: J Clin Oncol Date: 2009-02-02 Impact factor: 44.544

Review 10. Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis.

Authors: André Bacellar Costa Lima; Ligia T Macedo; André Deeke Sasse
Journal: PLoS One Date: 2011-08-02 Impact factor: 3.240

3 in total